Corporate Investor

Updated:

BBCA Pharmaceutical

Anhui BBCA Pharmaceutical was established in 1997. Li Wei serves as chairman of the parent BBCA Group that controls the listed vehicle. The firm produces...

BBCA Pharmaceutical

Anhui BBCA Pharmaceutical was established in 1997. Li Wei serves as chairman of the parent BBCA Group that controls the listed vehicle. The firm produces pharmaceutical preparations, raw materials, and operates commercial logistics inside China. The company owns 100 percent of Anhui BBCA Likang Pharmaceutical, Maanshan BBCA Pharmaceutical, and BBCA Pharmacy Chain. It also holds Anhui BBCA Pharmaceutical Marketing and Anhui Koyo Imp. & Exp. All facilities sit inside Anhui province. Investment posture centers on direct ownership of operating businesses rather than external fund commitments. Public equity value stands at 665 million USD. The firm maintains three production sites and a retail network of over 600 pharmacies. No additional offices outside Anhui are recorded. Recent participation includes a November 2025 panel on medical food innovation. Ownership flows through BBCA Group as the major shareholder. Governance includes independent directors and supervisors appointed since 2021.

General information

Firm type

Corporate Investor

Year founded

1997

AUM

665 (Altss estimate)

Location

Region

Asia

Country

China

City

Hefei

Corporate office

No. 16, Dalian Road, Baohe Industrial Park, Hefei, Anhui, China

Principals

Li Wei

Chairman

Sector focus

PharmaceuticalsHealthcare

Frequently asked questions

Who runs investment decisions at BBCA Pharmaceutical?

Li Wei serves as chairman of the controlling BBCA Group. Day-to-day operations are managed through the listed company's board and subsidiary entities.

Does BBCA Pharmaceutical participate in fund commitments or only direct deals?

The firm holds 100 percent ownership stakes in operating subsidiaries. No external fund commitments are recorded in available data.

What investment stages does BBCA Pharmaceutical typically target?

Activity centers on direct ownership of established pharmaceutical manufacturing and retail businesses inside China.

Where does the underlying wealth come from?

Value derives from the listed equity of Anhui BBCA Pharmaceutical Co., Ltd. on the Shenzhen Stock Exchange.

How is BBCA Pharmaceutical related to BBCA Group?

BBCA Group acts as parent and major shareholder of the listed pharmaceutical company.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Hefei Corporate Investor profiles